Quest Laboratories Ltd
QUESTLABQuest Laboratories Ltd
QUESTLAB
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 6.29 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Quest Laboratories Ltd manufactures a wide range of pharmaceutical formulations, including antibiotics and OTC drugs, available in various forms such as tablets and syrups.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 30.43 | 59.54 | 61.87 | 82.79 | — | |||||
Raw Materials | 24.43 | 44.27 | 41.72 | 52.29 | — | |||||
| Power & Fuel Cost | 0.40 | 0.58 | 0.79 | 0.87 | ||||||
| Employee Cost | 2.11 | 3.04 | 2.80 | 3.64 | ||||||
| Selling & Administrative Expenses | 1.39 | 3.16 | 5.32 | 7.02 | ||||||
| Operating & Other expenses | 0.61 | 1.96 | 3.13 | 3.18 | ||||||
EBITDA | 1.49 | 6.53 | 8.11 | 15.79 | — | |||||
| Depreciation/Amortization | 0.39 | 0.46 | 0.55 | 0.57 | — | |||||
| PBIT | 1.10 | 6.07 | 7.56 | 15.22 | — | |||||
| Interest & Other Items | 0.31 | 0.30 | 0.58 | 0.78 | — | |||||
| PBT | 0.79 | 5.77 | 6.98 | 14.44 | — | |||||
| Taxes & Other Items | 0.14 | 1.66 | 1.94 | 4.36 | — | |||||
| Net Income | 0.65 | 4.11 | 5.04 | 10.08 | — | |||||
| EPS | 6.03 | 38.10 | 46.72 | 15.49 | — | |||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | — | |||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | — |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Quest Laboratories Ltd | 17.88 | 6.29 | — |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare QUESTLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 11.87%
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 4.60%
Shareholding Pattern
Mar 2024
May 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
QUESTLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeQuest Laboratories will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Quest Laboratories announced that the 26th Annual General Meeting (AGM) of the company will be held on 4 September 2024.Powered by Capital Market - Live
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant